Goodpasture syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 12: Line 12:


==Overview==
==Overview==
he [[pathogenesis]] of Goodpasture syndrome includes the presence of [[Autoantibody|autoantibodies]] directed against the [[glomerular]] or [[alveolar]] [[Basement membrane|basement membrane.]] As with many [[autoimmune]] conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a [[type II hypersensitivity]] reaction to Goodpasture’s [[antigens]] on the [[cells]] of the [[glomeruli]] of the [[kidneys]] and the [[Pulmonary alveolus|pulmonary alveoli]], specifically the [[basement membrane]]'s (including a-3 chain of [[type IV collagen]]), whereby the [[immune system]] wrongly recognizes these cells as foreign and attacks and destroys them, as it would an invading pathogen. The target [[antigen]] that has the strongest pathogenic effect on [[Goodpasture disease|anti-GBM disease]] is the non-collagenous 1 domain of alpha-3 [[type IV collagen]]. There is strong correlation of [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane]] disease with allele HLA DRB1-1501. This [[allele]] is associated in causing [[renal injury]]. On gross pathology, Goodpasture syndrome with lung involvement may present with diffuse [[pulmonary hemorrhage]]. On microscopic [[histopathological]] analysis, early focal proliferative changes that display [[necrosis]] and crescent formation with an inflamed [[interstitial]] are seen. Under direct immunofluorescence,  linear [[immunoglobulin G]] deposits are found encompassing the [[glomerular basement membrane]] and at times the distal [[tubular]] portion of the [[Basement membrane|basement membrane.]]
The [[pathogenesis]] of Goodpasture syndrome includes the presence of [[Autoantibody|autoantibodies]] directed against the [[glomerular]] and/or [[alveolar]] [[Basement membrane|basement membrane.]] As with many [[autoimmune]] conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a [[type II hypersensitivity]] reaction to Goodpasture’s [[antigens]] on the [[cells]] of the [[glomeruli]] of the [[kidneys]] and the [[Pulmonary alveolus|pulmonary alveoli]]. The [[basement membrane]] (including a triple chain [[type IV collagen]]) lining the [[alveoli]] and [[glomeruli]] is particularly damaged in patients suffering from Goodpasture syndrome. The [[immune system]] misreads self-[[tissues]] as foreign, which leads to attack and destruction, as it would happen in case of an invading [[pathogen]]. The target [[antigen]] that is associated with the strongest pathogenic effect in [[Goodpasture disease|anti-GBM disease]] is the non-collagenous 1 domain of alpha-3 [[type IV collagen]]. There is strong correlation of [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane]] disease with allele HLA DRB1-1501. This [[allele]] is associated with [[renal injury]]. On [[gross pathology]], Goodpasture syndrome with lung involvement may present with diffuse [[pulmonary hemorrhage]]. On microscopic [[histopathological]] analysis, early focal proliferative changes that display [[necrosis]] and crescent formation (due to hypercellular [[glomeruli]]) with an inflamed [[interstitium]] are seen. Under direct [[immunofluorescence]],  linear [[immunoglobulin G]] deposits are found encompassing the [[glomerular basement membrane]] and at times the distal [[tubular]] portion of the [[Basement membrane|basement membrane.]]


==Pathogenesis==
==Pathogenesis==
Goodpasture syndrome is an [[autoimmune]] condition resulting from [[antibodies]] against the [[glomerular]] and [[alveolar]] [[basement membrane]]. It is thought Goodpasture syndrome is the result of [[type II hypersensitivity]] reaction which leads to generation of [[antibodies]] which bind [[antigenic]] proteins of [[glomerular]] and [[alveolar]] [[basement membrane]]. The antigen-antibody complex leads to activation of [[complement system]] and [[tissue]] destruction.<ref name="pmid19741587">{{cite journal |vauthors=Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH |title=Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity |journal=Kidney Int. |volume=76 |issue=10 |pages=1108–15 |date=November 2009 |pmid=19741587 |doi=10.1038/ki.2009.348 |url=}}</ref><ref name="pmid26200622">{{cite journal |vauthors=Xie LJ, Cui Z, Jia XY, Chen Z, Liu XR, Zhao MH |title=Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report |journal=Medicine (Baltimore) |volume=94 |issue=29 |pages=e1179 |date=July 2015 |pmid=26200622 |doi=10.1097/MD.0000000000001179 |url=}}</ref>
Goodpasture syndrome is an [[autoimmune]] condition resulting from [[antibodies]] against the [[glomerular]] and [[alveolar]] [[basement membrane]]. It is thought that Goodpasture syndrome is the result of [[type II hypersensitivity]] reaction which leads to generation of [[antibodies]] which bind [[antigenic]] proteins of [[glomerular]] and [[alveolar]] [[basement membrane]]. The [[antigen]]-[[antibody]] complex leads to activation of [[complement system]] and [[tissue]] destruction.<ref name="pmid19741587">{{cite journal |vauthors=Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH |title=Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity |journal=Kidney Int. |volume=76 |issue=10 |pages=1108–15 |date=November 2009 |pmid=19741587 |doi=10.1038/ki.2009.348 |url=}}</ref><ref name="pmid26200622">{{cite journal |vauthors=Xie LJ, Cui Z, Jia XY, Chen Z, Liu XR, Zhao MH |title=Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report |journal=Medicine (Baltimore) |volume=94 |issue=29 |pages=e1179 |date=July 2015 |pmid=26200622 |doi=10.1097/MD.0000000000001179 |url=}}</ref>


===Anatomy===
===Anatomy===
Line 22: Line 22:




The key for the renal corpuscle figure is: A – Renal corpuscle, B – Proximal tubule, C – Distal convoluted tubule, D – Juxtaglomerular apparatus, 1. [[Basement membrane]] (Basal lamina), 2. Bowman's capsule – parietal layer, 3. Bowman's capsule – visceral layer, 3a. Pedicels (Foot processes from podocytes), 3b. Podocyte, 4. Bowman's space (urinary space), 5a. Mesangium – Intraglomerular cell, 5b. Mesangium – Extraglomerular cell, 6. Granular cells (Juxtaglomerular cells), 7. Macula densa, 8. Myocytes (smooth muscle), 9. Afferent arteriole, 10. Glomerulus Capillaries, 11. Efferent arteriole.
The key for the renal corpuscle figure is: A – [[Renal corpuscle]], B – [[Proximal tubule]], C – [[Distal convoluted tubule]], D – [[Juxtaglomerular apparatus]], 1. [[Basement membrane]] (Basal lamina), 2. [[Bowman's capsule]] – parietal layer, 3. [[Bowman's capsule]] – visceral layer, 3a. Pedicels (Foot processes from [[podocytes]]), 3b. [[Podocyte]], 4. [[Bowman's space]] (urinary space), 5a. [[Mesangium]] – Intraglomerular cell, 5b. [[Mesangium]] – Extraglomerular cell, 6. Granular cells ([[Juxtaglomerular cells]]), 7. [[Macula densa]], 8. [[Myocytes]] ([[smooth muscle]]), 9. [[Afferent arteriole]], 10. Glomerulus [[Capillaries]], 11. [[Efferent arteriole]].
===Pathophysiology===
===Pathophysiology===
*The basement membrane (in general) is primarily made up of [[type IV collagen]].  
*The basement membrane (in general) is primarily made up of [[type IV collagen]].  
*The [[Type-IV collagen|type IV collagen]] is made of three alpha subunits of collagen, which form a triple [[helix]].
*The [[Type-IV collagen|type IV collagen]] is made of three alpha subunits of [[collagen]], which form a triple [[helix]].
*The alpha subunits of [[Type-IV collagen|type IV collagen]] can be of six different types and named as alpha1 to alpha6.
*The alpha subunits of [[Type-IV collagen|type IV collagen]] can be of six different types and named as alpha1 to alpha6.
*Each alpha subunit is further bound to three components namely:
*Each alpha subunit is further bound to three components namely:
**The [[amino terminus]] of alpha chain is bound by a short 7S domain.
**The [[amino terminus]] of alpha chain is bound by a short 7S domain.
**The [[carboxyl terminus]] is bound by a triple helix of alpha chains.
**The [[carboxyl terminus]] is bound by a triple helix of alpha chains.
**Lastly the alpha chain has a non-collagenous component.
**Lastly the alpha chain has a non-[[collagenous]] component.
*The [[autoantibodies]] in Goodpasture syndrome is directed against the non-collagenous components of the alpha3 chain of [[type IV collagen]].
*The [[autoantibodies]] in Goodpasture syndrome are directed against the non-[[collagenous]] components of the alpha3 chain of [[type IV collagen]].
*The target [[antigen]] that has the strongest pathogenic effect on anti-GBM disease is the non-collagenous 1 [[domain]] of alpha-3 [[type IV collagen]].<ref name="pmid19741587" />
*The target [[antigen]] that is associated with the strongest pathogenic effect in [[Goodpasture disease|anti-GBM disease]] is the non-collagenous 1 domain of alpha-3 [[type IV collagen]]<ref name="pmid19741587" />
*There are two dominant [[epitopes]] such as epitope A (17-31) and epitope B(127-141) and are seen in the alpha-3 non-collagenous 1 [[domain]] of [[type IV collagen]]. The [[antibodies]] do not normally bind unless a change has occurred in the non-cross linked hexamers or trimers.
*There are two dominant [[epitopes]] called epitope A (17-31) and epitope B(127-141) and are seen in the alpha-3 non-collagenous 1 [[domain]] of [[type IV collagen]]. The [[antibodies]] do not normally bind unless a change has occurred in the non-cross linked hexamers or trimers.
*In Goodpasture syndrome, these [[epitopes]] undergo a transitional change in the non-cross linked hexamers or trimers. This allows [[antibodies]] to be bound to these [[epitopes]].<ref name="pmid23085731">{{cite journal |vauthors=Chen JL, Hu SY, Jia XY, Zhao J, Yang R, Cui Z, Zhao MH |title=Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury |journal=Clin J Am Soc Nephrol |volume=8 |issue=1 |pages=51–8 |date=January 2013 |pmid=23085731 |pmc=3531658 |doi=10.2215/CJN.05140512 |url=}}</ref>
*In Goodpasture syndrome, these [[epitopes]] undergo a transitional change in the non-cross linked hexamers or trimers. This allows [[antibodies]] to be bound to these [[epitopes]].<ref name="pmid23085731">{{cite journal |vauthors=Chen JL, Hu SY, Jia XY, Zhao J, Yang R, Cui Z, Zhao MH |title=Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury |journal=Clin J Am Soc Nephrol |volume=8 |issue=1 |pages=51–8 |date=January 2013 |pmid=23085731 |pmc=3531658 |doi=10.2215/CJN.05140512 |url=}}</ref>
**The pathogenic role of [[epitopes]] such as epitope A, has been shown to affect the function of the renals, especially of the alpha-3 [[type IV collagen]] of non-collagenous 1 domain.
**The pathogenic role of [[epitopes]] such as epitope A, has been shown to affect the renal function, especially of the alpha-3 [[type IV collagen]] of non-[[collagenous]] 1 domain.
**Epitope B however is not able to induce Goodpasture syndrome by itself.
**Epitope B however is not able to induce Goodpasture syndrome by itself.
**In addition, [[antibodies]] may be directed against other components of alpha3 chain.
**In addition, [[antibodies]] may be directed against other components of alpha3 chain.
*Even though the [[basement membrane]] of various tissues are similar in structure, the [[antibodies]] are reactive only against [[glomerular]] and [[alveolar]] membranes.
*Even though the [[basement membrane]] of various tissues are similar in structure, the [[antibodies]] are reactive only against [[glomerular]] and [[alveolar]] membranes.
*This can be attributed to the fact that [[glomerular]] and [[alveolar]] [[basement membrane]] have greater expression and availability of [[epitopes]] for [[antibody]] binding. Moreover, the structure of [[glomerular]] and [[alveolar]] membrane is such that it promotes easy access to [[antibodies]] in these places.
*This can be attributed to the fact that [[glomerular]] and [[alveolar]] [[basement membrane]] have greater expression and availability of [[epitopes]] for [[antibody]] binding. Moreover, the structure of [[glomerular]] and [[alveolar]] membrane is such that it promotes easy access to [[antibodies]] in these places.
*Under pathological conditions seen with any type of [[lung]] injury, [[vascular permeability]] of the respiratory membrane is increased which further promotes [[antibody]] accumulation in the [[alveolar]] basement membrane.
*Under pathological conditions seen with any type of [[lung]] injury, [[vascular permeability]] of the respiratory membrane is increased, which further promotes [[antibody]] accumulation in the [[alveolar]] basement membrane.
*The cause of [[renal injury]] is due to [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane antibodies]] ability to bind and activate [[complement system]] and [[proteases]], resulting in an interruption between the [[filtration]] barrier and the Bowman’s capsule.  
*The cause of [[renal injury]] is due to [[Anti-glomerular basement membrane antibody|anti-glomerular basement membrane antibodies]] ability to bind and activate [[complement system]] and [[proteases]], resulting in an interruption between the [[filtration]] barrier and the [[Bowman's capsule|Bowman’s capsule]].  
*The interruption of the Bowman's capsule and [[filtration]] barrier, induces [[Crescentic glomerulonephritis|crescent]] shaped antigen-antibody complex formation in the [[Renal corpuscles|renal corpuscles,]] invoking [[proteinuria]] and activating [[T cells]] ([[CD4+]] and [[CD8+ T cells|CD8+]]), [[macrophages]], and [[neutrophils]].<ref name="pmid12815141">{{cite journal |vauthors=Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG |title=Alport's syndrome, Goodpasture's syndrome, and type IV collagen |journal=N. Engl. J. Med. |volume=348 |issue=25 |pages=2543–56 |date=June 2003 |pmid=12815141 |doi=10.1056/NEJMra022296 |url=}}</ref><ref name="pmid21168945">{{cite journal |vauthors=Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH |title=Clinical features and outcomes of anti-glomerular basement membrane disease in older patients |journal=Am. J. Kidney Dis. |volume=57 |issue=4 |pages=575–82 |date=April 2011 |pmid=21168945 |doi=10.1053/j.ajkd.2010.09.022 |url=}}</ref>
*The interruption of the [[Bowman's capsule]] and [[filtration]] barrier, induces [[Crescentic glomerulonephritis|crescent]] shaped antigen-antibody complex formation in the [[Renal corpuscles|renal corpuscles,]] invoking [[proteinuria]] and activating [[T cells]] ([[CD4+]] and [[CD8+ T cells|CD8+]]), [[macrophages]], and [[neutrophils]].<ref name="pmid12815141">{{cite journal |vauthors=Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG |title=Alport's syndrome, Goodpasture's syndrome, and type IV collagen |journal=N. Engl. J. Med. |volume=348 |issue=25 |pages=2543–56 |date=June 2003 |pmid=12815141 |doi=10.1056/NEJMra022296 |url=}}</ref><ref name="pmid21168945">{{cite journal |vauthors=Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH |title=Clinical features and outcomes of anti-glomerular basement membrane disease in older patients |journal=Am. J. Kidney Dis. |volume=57 |issue=4 |pages=575–82 |date=April 2011 |pmid=21168945 |doi=10.1053/j.ajkd.2010.09.022 |url=}}</ref>
*Conditions such as [[oxidation]], [[nitrosylation]], [[glycation]], increased [[body temperature]], or [[proteolytic]] cleavage can further lead to increased antigen-antibody cross reaction and early symptom onset.<ref name="pmid21124085">{{cite journal |vauthors=Peto P, Salama AD |title=Update on antiglomerular basement membrane disease |journal=Curr Opin Rheumatol |volume=23 |issue=1 |pages=32–7 |date=January 2011 |pmid=21124085 |doi=10.1097/BOR.0b013e328341009f |url=}}</ref>
*Conditions such as [[oxidation]], [[nitrosylation]], [[glycation]], increased [[body temperature]], or [[proteolytic]] cleavage can further lead to increased [[antigen]]-[[antibody]] cross reaction and early symptom onset.<ref name="pmid21124085">{{cite journal |vauthors=Peto P, Salama AD |title=Update on antiglomerular basement membrane disease |journal=Curr Opin Rheumatol |volume=23 |issue=1 |pages=32–7 |date=January 2011 |pmid=21124085 |doi=10.1097/BOR.0b013e328341009f |url=}}</ref>
**It has been shown that [[proteolytic]] cleavage of [[disulfide bonds]] in non-cross linked hexamers has shown greater affinity for Goodpasture syndrome [[antibodies]] to bind.
**It has been shown that [[proteolytic]] cleavage of [[disulfide bonds]] in non-cross linked hexamers has shown greater affinity for Goodpasture syndrome [[antibodies]] to bind.
**Environmental factors also contribute to the disease such as exposures to [[hydrocarbons]], exposure to [[formaldehyde]] or [[smoking]] tobacco.
**Environmental factors also contribute to the disease such as exposures to [[hydrocarbons]], exposure to [[formaldehyde]] or [[smoking]] [[tobacco]].
**[[Smoking]] tobacco for instance causes inhibition of sulfilimine bond substances. Inhibition of the sulfilimine bond substances cause non-cross linked hexamers to form.<ref name="pmid20660402">{{cite journal |vauthors=Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG |title=Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis |journal=N. Engl. J. Med. |volume=363 |issue=4 |pages=343–54 |date=July 2010 |pmid=20660402 |pmc=4144421 |doi=10.1056/NEJMoa0910500 |url=}}</ref>
**[[Smoking]] [[tobacco]] for instance causes inhibition of sulfilimine bond substances. Inhibition of the sulfilimine bond substances cause non-cross linked hexamers to form.<ref name="pmid20660402">{{cite journal |vauthors=Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG |title=Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis |journal=N. Engl. J. Med. |volume=363 |issue=4 |pages=343–54 |date=July 2010 |pmid=20660402 |pmc=4144421 |doi=10.1056/NEJMoa0910500 |url=}}</ref>


==Genes==
==Genes==
[[Genes]] involved in the pathogenesis of Goodpasture syndrome include certain [[alleles]] of [[human leukocyte antigen]] (HLA).<ref name="pmid26200622">{{cite journal| author=Xie LJ, Cui Z, Jia XY, Chen Z, Liu XR, Zhao MH| title=Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report. | journal=Medicine (Baltimore) | year= 2015 | volume= 94 | issue= 29 | pages= e1179 | pmid=26200622 | doi=10.1097/MD.0000000000001179 | pmc=4603008 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26200622  }}</ref> <ref name="pmid27049372">{{cite journal| author=Couser WG| title=Pathogenesis and treatment of glomerulonephritis-an update. | journal=J Bras Nefrol | year= 2016 | volume= 38 | issue= 1 | pages= 107-22 | pmid=27049372 | doi=10.5935/0101-2800.20160016 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27049372  }}</ref>
[[Genes]] involved in the [[pathogenesis]] of Goodpasture syndrome include certain [[alleles]] of [[human leukocyte antigen]] (HLA).<ref name="pmid26200622">{{cite journal| author=Xie LJ, Cui Z, Jia XY, Chen Z, Liu XR, Zhao MH| title=Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report. | journal=Medicine (Baltimore) | year= 2015 | volume= 94 | issue= 29 | pages= e1179 | pmid=26200622 | doi=10.1097/MD.0000000000001179 | pmc=4603008 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26200622  }}</ref> <ref name="pmid27049372">{{cite journal| author=Couser WG| title=Pathogenesis and treatment of glomerulonephritis-an update. | journal=J Bras Nefrol | year= 2016 | volume= 38 | issue= 1 | pages= 107-22 | pmid=27049372 | doi=10.5935/0101-2800.20160016 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27049372  }}</ref>
*[[HLA-B27]] has been found to be more frequently associated with severe nephritic form of Goodpasture syndrome.
*[[HLA-B27]] has been found to be more frequently associated with severe [[Nephritic syndrome|nephritic]] form of Goodpasture syndrome.
*Other [[alleles]] associated with Goodpasture syndrome include increased frequency of [[HLA-DR15]] and DRB1*03, DRB1*04 and a decreased frequency of DRB1*01 and DRB1*07.
*Other [[alleles]] associated with Goodpasture syndrome include increased frequency of [[HLA-DR15]] and DRB1*03, DRB1*04 and a decreased frequency of DRB1*01 and DRB1*07.
*Goodpasture disease is also strongly associated with the DRB1*1501 and to DRB1*1502 [[allele]].
*Goodpasture disease is also strongly associated with the DRB1*1501 and to DRB1*1502 [[allele]].
*The allele DRB1*1501 is primarily associated with causing [[renal injury]] and estimated to be present in 80% of patients with Goodpasture syndrome,
*The allele DRB1*1501 is primarily associated with causing [[renal injury]] and estimated to be present in 80% of patients with Goodpasture syndrome,
*Recent studies have shown that DRB1*1501 [[allele]] is found in approximately one third caucasian patients with Goodpasture syndrome.
*Recent studies have shown that DRB1*1501 [[allele]] is found in approximately one third of Caucasian patients with Goodpasture syndrome.


==Gross Pathology==
==Gross Pathology==
On gross pathology, Goddpasture syndrome with lung involvement may present with diffuse [[pulmonary hemorrhage]].
On [[gross pathology]], Goddpasture syndrome with lung involvement may present with diffuse [[pulmonary hemorrhage]].
[[image:Diffuse pulmonary hemorrhage in Goodpasture syndrome.jpg|thumb|center|Diffuse pulmonary hemorrhage in Goodpasture syndrome ([Case ourtesy of Yale Rosen, MD https://www.flickr.com/photos/pulmonary_pathology/3731499661])]]
[[image:Diffuse pulmonary hemorrhage in Goodpasture syndrome.jpg|thumb|center|Diffuse pulmonary hemorrhage in Goodpasture syndrome ([Case ourtesy of Yale Rosen, MD https://www.flickr.com/photos/pulmonary_pathology/3731499661])]]


==Microscopic Pathology==
==Microscopic Pathology==
On microscopic [[histopathological]] analysis, findings include:<ref name="pmid16478866">{{cite journal |vauthors=Frankel SK, Cosgrove GP, Fischer A, Meehan RT, Brown KK |title=Update in the diagnosis and management of pulmonary vasculitis |journal=Chest |volume=129 |issue=2 |pages=452–65 |date=February 2006 |pmid=16478866 |doi=10.1378/chest.129.2.452 |url=}}</ref><ref name="pmid19364515">{{cite journal |vauthors=Zhao J, Yan Y, Cui Z, Yang R, Zhao MH |title=The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity |journal=Hum. Immunol. |volume=70 |issue=6 |pages=425–9 |date=June 2009 |pmid=19364515 |doi=10.1016/j.humimm.2009.04.004 |url=}}</ref><ref name="crescent glomerulonephritis">University of Pittsburgh Medical Center Pathology. www.path.upmc.edu/cases/case541.html Accessed on Novermber 2nd 2016</ref><ref name="pmid25462583">{{cite journal| author=Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G et al.| title=Goodpasture's syndrome: a clinical update. | journal=Autoimmun Rev | year= 2015 | volume= 14 | issue= 3 | pages= 246-53 | pmid=25462583 | doi=10.1016/j.autrev.2014.11.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25462583  }}</ref>
On microscopic [[histopathological]] analysis, findings include:<ref name="pmid16478866">{{cite journal |vauthors=Frankel SK, Cosgrove GP, Fischer A, Meehan RT, Brown KK |title=Update in the diagnosis and management of pulmonary vasculitis |journal=Chest |volume=129 |issue=2 |pages=452–65 |date=February 2006 |pmid=16478866 |doi=10.1378/chest.129.2.452 |url=}}</ref><ref name="pmid19364515">{{cite journal |vauthors=Zhao J, Yan Y, Cui Z, Yang R, Zhao MH |title=The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity |journal=Hum. Immunol. |volume=70 |issue=6 |pages=425–9 |date=June 2009 |pmid=19364515 |doi=10.1016/j.humimm.2009.04.004 |url=}}</ref><ref name="crescent glomerulonephritis">University of Pittsburgh Medical Center Pathology. www.path.upmc.edu/cases/case541.html Accessed on Novermber 2nd 2016</ref><ref name="pmid25462583">{{cite journal| author=Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G et al.| title=Goodpasture's syndrome: a clinical update. | journal=Autoimmun Rev | year= 2015 | volume= 14 | issue= 3 | pages= 246-53 | pmid=25462583 | doi=10.1016/j.autrev.2014.11.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25462583  }}</ref>
* In [[kidneys]], early focal proliferative changes that display [[necrosis]] and [[Crescentic glomerulonephritis|crescent]] formation (in 75% of glomeruli) with an inflamed [[interstitial]] are seen.
* In [[kidneys]], early focal proliferative changes that display [[necrosis]] and [[Crescentic glomerulonephritis|crescent]] formation (in 75% of glomeruli) with an inflamed [[interstitium]] are seen.
* Linear staining of [[IgG]] & [[C3-convertase|C3]] along the GBM (characteristic) with renal tubular [[necrosis]] and loss (tubular portion of the [[basement membrane]]).
* Linear staining of [[IgG]] & [[C3-convertase|C3]] along the glomerular basement membrane (characteristic) with [[renal tubular necrosis]] and loss of tubular portion of the [[basement membrane]]
* Other features of proliferative or [[necrotizing]] [[glomerulonephritis]].
* Other features of proliferative or [[necrotizing]] [[glomerulonephritis]].
* In lungs, findings include neutrophilic capillaritis, [[Hyaline membrane disease|hyaline membrane]] (in [[alveoli]]) and diffuse alveolar hemorrhage.  
* In [[lungs]], findings include [[Neutrophilia|neutrophilic]] infiltration of the [[capillaries]], [[Hyaline membrane disease|hyaline membrane]] (in [[alveoli]]) and diffuse alveolar hemorrhage.  


*The following are images of the microscopic pathology of crescent glomerulonephritis and the [[immunofluorescence]] of linear IgG and C3 deposition.  
*The following are images of the microscopic pathology of crescent glomerulonephritis and the [[immunofluorescence]] of linear [[Immunoglobulin G|IgG]] and C3 deposition.  
[[File:512px-Crescentic glomerulonephritis - intermed mag.jpg|thumb|left|Crescentic glomerulonephritis ([By Nephron [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], from Wikimedia Commons])]]
[[File:512px-Crescentic glomerulonephritis - intermed mag.jpg|thumb|left|Crescentic glomerulonephritis ([By Nephron [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], from Wikimedia Commons])]]


[[Image:Goodpasture Disease.jpg|thumb|center|Goodpasture Disease depicting linear IgG & C3 deposits around GBM. <ref>http://picasaweb.google.com/mcmumbi/USMLEIIImages</ref>]]
[[Image:Goodpasture Disease.jpg|thumb|center|Goodpasture Disease depicting linear IgG & C3 deposits around GBM. <ref>http://picasaweb.google.com/mcmumbi/USMLEIIImages</ref>]]
<br style="clear:left">


==References==
==References==

Latest revision as of 13:21, 6 May 2018

Title
https://https://www.youtube.com/watch?v=vAX2UMA8Oek%7C350}}

Goodpasture syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Goodpasture syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goodpasture syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Goodpasture syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goodpasture syndrome pathophysiology

CDC on Goodpasture syndrome pathophysiology

Goodpasture syndrome pathophysiology in the news

Blogs on Goodpasture syndrome pathophysiology

Directions to Hospitals Treating Goodpasture syndrome

Risk calculators and risk factors for Goodpasture syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3] Akshun Kalia M.B.B.S.[4]

Overview

The pathogenesis of Goodpasture syndrome includes the presence of autoantibodies directed against the glomerular and/or alveolar basement membrane. As with many autoimmune conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a type II hypersensitivity reaction to Goodpasture’s antigens on the cells of the glomeruli of the kidneys and the pulmonary alveoli. The basement membrane (including a triple chain type IV collagen) lining the alveoli and glomeruli is particularly damaged in patients suffering from Goodpasture syndrome. The immune system misreads self-tissues as foreign, which leads to attack and destruction, as it would happen in case of an invading pathogen. The target antigen that is associated with the strongest pathogenic effect in anti-GBM disease is the non-collagenous 1 domain of alpha-3 type IV collagen. There is strong correlation of anti-glomerular basement membrane disease with allele HLA DRB1-1501. This allele is associated with renal injury. On gross pathology, Goodpasture syndrome with lung involvement may present with diffuse pulmonary hemorrhage. On microscopic histopathological analysis, early focal proliferative changes that display necrosis and crescent formation (due to hypercellular glomeruli) with an inflamed interstitium are seen. Under direct immunofluorescence, linear immunoglobulin G deposits are found encompassing the glomerular basement membrane and at times the distal tubular portion of the basement membrane.

Pathogenesis

Goodpasture syndrome is an autoimmune condition resulting from antibodies against the glomerular and alveolar basement membrane. It is thought that Goodpasture syndrome is the result of type II hypersensitivity reaction which leads to generation of antibodies which bind antigenic proteins of glomerular and alveolar basement membrane. The antigen-antibody complex leads to activation of complement system and tissue destruction.[1][2]

Anatomy

Renal corpuscle. (Source: [Michal Komorniczak (Poland)[CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)], from Wikimedia Commons])
Alveolar wall ([By Cruithne9 [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)], from Wikimedia Commons])


The key for the renal corpuscle figure is: A – Renal corpuscle, B – Proximal tubule, C – Distal convoluted tubule, D – Juxtaglomerular apparatus, 1. Basement membrane (Basal lamina), 2. Bowman's capsule – parietal layer, 3. Bowman's capsule – visceral layer, 3a. Pedicels (Foot processes from podocytes), 3b. Podocyte, 4. Bowman's space (urinary space), 5a. Mesangium – Intraglomerular cell, 5b. Mesangium – Extraglomerular cell, 6. Granular cells (Juxtaglomerular cells), 7. Macula densa, 8. Myocytes (smooth muscle), 9. Afferent arteriole, 10. Glomerulus Capillaries, 11. Efferent arteriole.

Pathophysiology

Genes

Genes involved in the pathogenesis of Goodpasture syndrome include certain alleles of human leukocyte antigen (HLA).[2] [8]

  • HLA-B27 has been found to be more frequently associated with severe nephritic form of Goodpasture syndrome.
  • Other alleles associated with Goodpasture syndrome include increased frequency of HLA-DR15 and DRB1*03, DRB1*04 and a decreased frequency of DRB1*01 and DRB1*07.
  • Goodpasture disease is also strongly associated with the DRB1*1501 and to DRB1*1502 allele.
  • The allele DRB1*1501 is primarily associated with causing renal injury and estimated to be present in 80% of patients with Goodpasture syndrome,
  • Recent studies have shown that DRB1*1501 allele is found in approximately one third of Caucasian patients with Goodpasture syndrome.

Gross Pathology

On gross pathology, Goddpasture syndrome with lung involvement may present with diffuse pulmonary hemorrhage.

Diffuse pulmonary hemorrhage in Goodpasture syndrome ([Case ourtesy of Yale Rosen, MD https://www.flickr.com/photos/pulmonary_pathology/3731499661])

Microscopic Pathology

On microscopic histopathological analysis, findings include:[9][10][11][12]

  • The following are images of the microscopic pathology of crescent glomerulonephritis and the immunofluorescence of linear IgG and C3 deposition.
Crescentic glomerulonephritis ([By Nephron [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0) or GFDL (http://www.gnu.org/copyleft/fdl.html)], from Wikimedia Commons])
Goodpasture Disease depicting linear IgG & C3 deposits around GBM. [13]


References

  1. ↑ 1.0 1.1 Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH (November 2009). "Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity". Kidney Int. 76 (10): 1108–15. doi:10.1038/ki.2009.348. PMID 19741587.
  2. ↑ 2.0 2.1 Xie LJ, Cui Z, Jia XY, Chen Z, Liu XR, Zhao MH (July 2015). "Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report". Medicine (Baltimore). 94 (29): e1179. doi:10.1097/MD.0000000000001179. PMID 26200622.
  3. ↑ Chen JL, Hu SY, Jia XY, Zhao J, Yang R, Cui Z, Zhao MH (January 2013). "Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury". Clin J Am Soc Nephrol. 8 (1): 51–8. doi:10.2215/CJN.05140512. PMC 3531658. PMID 23085731.
  4. ↑ Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG (June 2003). "Alport's syndrome, Goodpasture's syndrome, and type IV collagen". N. Engl. J. Med. 348 (25): 2543–56. doi:10.1056/NEJMra022296. PMID 12815141.
  5. ↑ Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH (April 2011). "Clinical features and outcomes of anti-glomerular basement membrane disease in older patients". Am. J. Kidney Dis. 57 (4): 575–82. doi:10.1053/j.ajkd.2010.09.022. PMID 21168945.
  6. ↑ Peto P, Salama AD (January 2011). "Update on antiglomerular basement membrane disease". Curr Opin Rheumatol. 23 (1): 32–7. doi:10.1097/BOR.0b013e328341009f. PMID 21124085.
  7. ↑ Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG (July 2010). "Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis". N. Engl. J. Med. 363 (4): 343–54. doi:10.1056/NEJMoa0910500. PMC 4144421. PMID 20660402.
  8. ↑ Couser WG (2016). "Pathogenesis and treatment of glomerulonephritis-an update". J Bras Nefrol. 38 (1): 107–22. doi:10.5935/0101-2800.20160016. PMID 27049372.
  9. ↑ Frankel SK, Cosgrove GP, Fischer A, Meehan RT, Brown KK (February 2006). "Update in the diagnosis and management of pulmonary vasculitis". Chest. 129 (2): 452–65. doi:10.1378/chest.129.2.452. PMID 16478866.
  10. ↑ Zhao J, Yan Y, Cui Z, Yang R, Zhao MH (June 2009). "The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity". Hum. Immunol. 70 (6): 425–9. doi:10.1016/j.humimm.2009.04.004. PMID 19364515.
  11. ↑ University of Pittsburgh Medical Center Pathology. www.path.upmc.edu/cases/case541.html Accessed on Novermber 2nd 2016
  12. ↑ Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G; et al. (2015). "Goodpasture's syndrome: a clinical update". Autoimmun Rev. 14 (3): 246–53. doi:10.1016/j.autrev.2014.11.006. PMID 25462583.
  13. ↑ http://picasaweb.google.com/mcmumbi/USMLEIIImages

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Goodpasture_syndrome_pathophysiology&oldid=1468979"